^
    Back
    Association details:
    Biomarker:SSTR Expression
    Cancer:Neuroendocrine Tumor
    Drug:AlphaMedix (ORM-2110) (Alpha radiation emitter, SSTR2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2021
    Title:

    Phase I dose-escalation study of AlphaMedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients.

    Published date:
    05/19/2021
    Excerpt:
    This F-I-H clinical study of AlphaMedix shows that PRRT with 212Pb is feasible, well tolerated, and provides substantial reduction in tumor burden to patients with unresectable, metastatic SSTR-expressing NETs.
    DOI:
    10.1200/JCO.2021.39.15_suppl.4117
    Trial ID:
    ALPHAMEDIX01